These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28442511)

  • 1. Circulating miRNA Profiles of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients.
    Todorova VK; Makhoul I; Wei J; Klimberg VS
    Ann Clin Lab Sci; 2017 Mar; 47(2):115-119. PubMed ID: 28442511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for Presymptomatic Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
    Todorova VK; Makhoul I; Siegel ER; Wei J; Stone A; Carter W; Beggs ML; Owen A; Klimberg VS
    PLoS One; 2016; 11(8):e0160224. PubMed ID: 27490685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Rigaud VO; Ferreira LR; Ayub-Ferreira SM; Ávila MS; Brandão SM; Cruz FD; Santos MH; Cruz CB; Alves MS; Issa VS; Guimarães GV; Cunha-Neto E; Bocchi EA
    Oncotarget; 2017 Jan; 8(4):6994-7002. PubMed ID: 28052002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. microRNA miR-133a as a Biomarker for Doxorubicin-Induced Cardiotoxicity in Women with Breast Cancer: A Signaling Pathway Investigation.
    Alves MT; da Conceição IMCA; de Oliveira AN; Oliveira HHM; Soares CE; de Paula Sabino A; Silva LM; Simões R; Luizon MR; Gomes KB
    Cardiovasc Toxicol; 2022 Jul; 22(7):655-662. PubMed ID: 35524907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
    Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity.
    Gioffré S; Ricci V; Vavassori C; Ruggeri C; Chiesa M; Alfieri I; Zorzan S; Buzzetti M; Milano G; Scopece A; Castiglioni L; Sironi L; Pompilio G; Colombo GI; D'Alessandra Y
    Biomed Pharmacother; 2019 Feb; 110():1-8. PubMed ID: 30453253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients.
    Ruggeri C; Gioffré S; Achilli F; Colombo GI; D'Alessandra Y
    Heart Fail Rev; 2018 Jan; 23(1):109-122. PubMed ID: 28944400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Specific Circulating MicroRNA Cluster Is Associated to Late Differential Cardiac Response to Doxorubicin-Induced Cardiotoxicity
    Ruggeri C; Gioffré S; Chiesa M; Buzzetti M; Milano G; Scopece A; Castiglioni L; Pontremoli M; Sironi L; Pompilio G; Colombo GI; D'Alessandra Y
    Dis Markers; 2018; 2018():8395651. PubMed ID: 30627229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleolin protects against doxorubicin-induced cardiotoxicity via upregulating microRNA-21.
    Sun H; Tong Z; Fang Y; Jiang B; Liang P; Tang Y; Li Y; Wu Y; Xiao X
    J Cell Physiol; 2018 Dec; 233(12):9516-9525. PubMed ID: 29968904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of inflammation, hypercoagulability and endothelial injury predict early asymptomatic doxorubicin-induced cardiotoxicity in breast cancer patients.
    Todorova VK; Hsu PC; Wei JY; Lopez-Candales A; Chen JZ; Su LJ; Makhoul I
    Am J Cancer Res; 2020; 10(9):2933-2945. PubMed ID: 33042627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating microRNAs and Cytokines as Prognostic Biomarkers for Doxorubicin-Induced Cardiac Injury and for Evaluating the Effectiveness of an Exercise Intervention.
    Jeyabal P; Bhagat A; Wang F; Roth M; Livingston JA; Gilchrist SC; Banchs J; Hildebrandt MAT; Chandra J; Deswal A; Koutroumpakis E; Wang J; Daw NC; Honey TA; Kleinerman ES
    Clin Cancer Res; 2023 Nov; 29(21):4430-4440. PubMed ID: 37651264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Oliveira-Carvalho V; Ferreira LR; Bocchi EA
    J Appl Toxicol; 2015 Sep; 35(9):1071-2. PubMed ID: 26046768
    [No Abstract]   [Full Text] [Related]  

  • 13. Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer.
    Hawkins PG; Sun Y; Dess RT; Jackson WC; Sun G; Bi N; Tewari M; Hayman JA; Kalemkerian GP; Gadgeel SM; Lawrence TS; Haken RKT; Matuszak MM; Kong FS; Schipper MJ; Jolly S
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1635-1643. PubMed ID: 30923943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.
    Robinson P; Kasembeli M; Bharadwaj U; Engineer N; Eckols KT; Tweardy DJ
    Biomed Res Int; 2016; 2016():1959270. PubMed ID: 26981525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-34a-5p as a promising early circulating preclinical biomarker of doxorubicin-induced chronic cardiotoxicity.
    Desai VG; Vijay V; Lee T; Han T; Moland CL; Phanavanh B; Herman EH; Stine K; Fuscoe JC
    J Appl Toxicol; 2022 Sep; 42(9):1477-1490. PubMed ID: 35199358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Nemade H; Gaspar JA; Hescheler J; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Dec; 90(12):3087-3098. PubMed ID: 26842497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA in the Diagnosis and Treatment of Doxorubicin-Induced Cardiotoxicity.
    Kuang Z; Wu J; Tan Y; Zhu G; Li J; Wu M
    Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular vesicular microRNAs as potential biomarker for early detection of doxorubicin-induced cardiotoxicity.
    Beaumier A; Robinson SR; Robinson N; Lopez KE; Meola DM; Barber LG; Bulmer BJ; Calvalido J; Rush JE; Yeri A; Das S; Yang VK
    J Vet Intern Med; 2020 May; 34(3):1260-1271. PubMed ID: 32255536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients.
    Todorova VK; Makhoul I; Dhakal I; Wei J; Stone A; Carter W; Owen A; Klimberg VS
    Oncol Res; 2017 Sep; 25(8):1223-1229. PubMed ID: 28256194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in HER2-positive and HER2-negative breast cancer patients.
    Thonusin C; Osataphan N; Leemasawat K; Nawara W; Sriwichaiin S; Supakham S; Gunaparn S; Apaijai N; Somwangprasert A; Phrommintikul A; Chattipakorn SC; Chattipakorn N
    J Transl Med; 2024 Apr; 22(1):398. PubMed ID: 38685030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.